Navigating the New EU Medical Devices Regulation: Retrospective Post-Market Follow-Up of Hyaluronic Acid Injections for Knee Osteoarthritis

Alejandro Alcina Navarro, Sara Gómez Valero, Mercedes Gimeno del Sol, María Pilar Coronel Granado
{"title":"Navigating the New EU Medical Devices Regulation: Retrospective Post-Market Follow-Up of Hyaluronic Acid Injections for Knee Osteoarthritis","authors":"Alejandro Alcina Navarro, Sara Gómez Valero, Mercedes Gimeno del Sol, María Pilar Coronel Granado","doi":"10.2147/oarrr.s446572","DOIUrl":null,"url":null,"abstract":"Purpose: The entry into force of the new Medical Device Regulation (EU) 2017/745 highlights the need for post-market clinical follow-up to ensure the safety and efficacy throughout the life cycle of medical devices. This study evaluates the efficacy and safety of a single intra-articular hyaluronic acid injection in knee osteoarthritis in real-world conditions, over a six-month period, aligning with the summary of safety and clinical performance (SSCP) required by the new regulation. Patients and Methods: Patients over 18 years of age with knee osteoarthritis, treated with a single injection of HA (Adant ® One, Meiji Pharma Spain, Spain) at a 3rd level hospital. Patients were treated and followed between January 1, 2020 and June 30, 2022. Demographic, clinical, and treatment-related data were collected, and efficacy regarding pain relief and/or function improvement was assessed using a Likert-type scale. Data were pseudo-anonymized and the comparison was performed using Fisher’ or Mann Whitney’ test. The study was approved by the Ethics Review Board of the Hospital Puerta de Hierro (Madrid, Spain). Results: We followed 20 patients with knee osteoarthritis, with a mean age of 61 years, 80% women, and with a high burden of comorbidities (90%). A total of 60% of patients presented Kellgren-Lawrence grade III–IV. Four patients (20%) returned before 6 months due to lack of efficacy. Of the other patients, 65% showed a clinical response that lasted more than 12 months in 38.5% of cases. Time until medical appointment and taking concomitant medication for knee osteoarthritis were associated with better clinical response (p < 0.05). Conclusion: The administration of a Adant ® One single intra-articular hyaluronic acid injection in knee osteoarthritis is effective, safe, and maintains the improvement over a six-month period. Our findings also emphasize the need of using standardized tools for accurate efficacy assessment and optimal patient care.","PeriodicalId":502804,"journal":{"name":"Open Access Rheumatology: Research and Reviews","volume":"4 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Rheumatology: Research and Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/oarrr.s446572","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The entry into force of the new Medical Device Regulation (EU) 2017/745 highlights the need for post-market clinical follow-up to ensure the safety and efficacy throughout the life cycle of medical devices. This study evaluates the efficacy and safety of a single intra-articular hyaluronic acid injection in knee osteoarthritis in real-world conditions, over a six-month period, aligning with the summary of safety and clinical performance (SSCP) required by the new regulation. Patients and Methods: Patients over 18 years of age with knee osteoarthritis, treated with a single injection of HA (Adant ® One, Meiji Pharma Spain, Spain) at a 3rd level hospital. Patients were treated and followed between January 1, 2020 and June 30, 2022. Demographic, clinical, and treatment-related data were collected, and efficacy regarding pain relief and/or function improvement was assessed using a Likert-type scale. Data were pseudo-anonymized and the comparison was performed using Fisher’ or Mann Whitney’ test. The study was approved by the Ethics Review Board of the Hospital Puerta de Hierro (Madrid, Spain). Results: We followed 20 patients with knee osteoarthritis, with a mean age of 61 years, 80% women, and with a high burden of comorbidities (90%). A total of 60% of patients presented Kellgren-Lawrence grade III–IV. Four patients (20%) returned before 6 months due to lack of efficacy. Of the other patients, 65% showed a clinical response that lasted more than 12 months in 38.5% of cases. Time until medical appointment and taking concomitant medication for knee osteoarthritis were associated with better clinical response (p < 0.05). Conclusion: The administration of a Adant ® One single intra-articular hyaluronic acid injection in knee osteoarthritis is effective, safe, and maintains the improvement over a six-month period. Our findings also emphasize the need of using standardized tools for accurate efficacy assessment and optimal patient care.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
驾驭新的欧盟医疗器械法规:透明质酸注射治疗膝骨关节炎的上市后回顾性随访
目的:新的《医疗器械法规》(欧盟)2017/745 的生效凸显了上市后临床跟踪的必要性,以确保医疗器械在整个生命周期内的安全性和有效性。本研究根据新法规要求的安全性和临床表现摘要(SSCP),评估了在真实世界条件下,单次关节内透明质酸注射治疗膝骨关节炎的疗效和安全性,为期六个月。患者和方法:18岁以上的膝关节骨关节炎患者,在一家三级医院接受单次注射HA(Adant ® One,西班牙明治制药公司)治疗。患者的治疗和随访时间为 2020 年 1 月 1 日至 2022 年 6 月 30 日。研究人员收集了患者的人口统计学、临床和治疗相关数据,并使用李克特量表评估了疼痛缓解和/或功能改善的疗效。数据采用假名化处理,比较采用费雪或曼-惠特尼检验。该研究获得了西班牙马德里 Puerta de Hierro 医院伦理审查委员会的批准。研究结果我们随访了20名膝关节骨性关节炎患者,平均年龄61岁,80%为女性,合并症较多(90%)。共有 60% 的患者患有凯尔格伦-劳伦斯 III-IV 级关节炎。有四名患者(20%)因疗效不佳在 6 个月前复诊。在其他患者中,65%的患者出现了临床反应,其中38.5%的病例持续了12个月以上。就诊时间和同时服用治疗膝关节骨关节炎的药物与更好的临床反应有关(P < 0.05)。结论Adant ® One单次关节内透明质酸注射治疗膝骨关节炎有效、安全,并能在6个月内保持改善。我们的研究结果还强调了使用标准化工具进行准确疗效评估和优化患者护理的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Autoantibodies Serum Level and 10-Year Risk of Fractures Evaluated by FRAX® Tool in Rheumatoid Arthritis Patients Basic Fibroblast Growth Factor Induces Matrix Metalloproteinase-13 via ERK MAP Kinase-Altered Phosphorylation and Sumoylation of Elk-1 in Human Adult Articular Chondrocytes [Expression of Concern] Towards Personalized Medicine in Rheumatoid Arthritis Motor Dysfunctions in Fibromyalgia Patients: The Importance of Breathing Navigating the New EU Medical Devices Regulation: Retrospective Post-Market Follow-Up of Hyaluronic Acid Injections for Knee Osteoarthritis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1